PARP Inhibitor Market

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.

PARP Inhibitor Market contains market size and forecasts of PARP (Poly ADP-Ribose Polymerase) Inhibitor in global, including the following market information:

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five PARP (Poly ADP-Ribose Polymerase) Inhibitor companies in 2021 (%)

The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market was valued at 4822.1 million in 2021 and is projected to reach US$ 8545.3 million by 2028, at a CAGR of 8.5% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Lynparza Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor include AstraZeneca, Tesaro, Merck & Co, Clovis Oncology, Pfizer, GSK and Zai Lab, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment Percentages, by Type, 2021 (%)

Lynparza

Zejula

Rubraca

Talzenna

Other

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment Percentages, by Application, 2021 (%)

Ovarian Cancer

Breast Cancer

Other

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies PARP (Poly ADP-Ribose Polymerase) Inhibitor revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies PARP (Poly ADP-Ribose Polymerase) Inhibitor revenues share in global market, 2021 (%)

Key companies PARP (Poly ADP-Ribose Polymerase) Inhibitor sales in global market, 2017-2022 (Estimated), (K Units)

Key companies PARP (Poly ADP-Ribose Polymerase) Inhibitor sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

AstraZeneca

Tesaro

Merck & Co

Clovis Oncology

Pfizer

GSK

Zai Lab